ReAlta Life Sciences Completes Oversubscribed $40M Financing to Support Pegtarazimod Phase 2 Development in Hypoxic Ischemic Encephalopathy (HIE)
ReAlta Life Sciences Inc. (“ReAlta”), a clinical-stage biopharmaceutical company focused on targeting neutrophil activity and key components of the complement system to address inflammatory diseases, has announced the successful completion of an oversubscribed $40 million financing round. With this latest capital infusion, the company’s total funding to date now exceeds $150 million, further strengthening its ability to advance its lead therapeutic candidate and broader pipeline.
The proceeds from the financing will primarily support the continued clinical development of pegtarazimod, a first-in-class investigational therapy being developed for Hypoxic Ischemic Encephalopathy (HIE). This severe and often life-threatening condition affects newborns and is caused by a lack of oxygen and blood flow to the brain during or around the time of birth. HIE is associated with high rates of mortality and long-term neurological impairment, including cerebral palsy, developmental delays, and cognitive deficits. Despite the seriousness of the condition, there are currently no approved drug therapies available, leaving clinicians with limited treatment options beyond supportive care and therapeutic hypothermia.
ReAlta’s lead program aims to address this critical unmet medical need by introducing a novel therapeutic approach that targets the underlying biological mechanisms driving brain injury in HIE. Pegtarazimod is designed to modulate both complement activation and neutrophil-driven inflammation, two key upstream processes implicated in the cascade of events that lead to neuronal damage following hypoxic injury. By intervening early in this inflammatory cascade, the therapy has the potential to reduce or prevent the progression of brain injury in affected newborns.
The company is currently advancing pegtarazimod through a Phase 2 clinical trial known as the STAR study, which is actively enrolling patients across 13 clinical sites in the United States. This study is designed to evaluate the safety, tolerability, and preliminary efficacy of the therapy in newborns diagnosed with HIE. Key upcoming milestones for the program include completion of patient enrollment, generation of top-line data from the trial, and a planned End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA). These milestones are expected to play a critical role in shaping the subsequent clinical and regulatory strategy for the program.
Howard Berman, Ph.D., Chief Executive Officer of ReAlta, highlighted both the scientific and humanitarian importance of the company’s work. He noted that HIE represents a devastating condition for which families and clinicians currently have few options, and emphasized that opportunities to work on programs with such a combination of scientific innovation and urgent patient need are rare. According to Berman, the strong investor participation in the financing round reflects a high level of confidence in the potential of pegtarazimod to fundamentally change the treatment landscape for this condition.
Berman further explained that pegtarazimod’s mechanism of action differentiates it from conventional approaches by targeting the root causes of inflammation rather than downstream effects. Complement activation and neutrophil infiltration are among the earliest drivers of tissue damage following hypoxic injury, and by modulating these pathways, the therapy seeks to interrupt the progression of injury before irreversible damage occurs. This upstream targeting strategy represents a shift in how HIE is approached therapeutically and may offer a more effective means of preserving neurological function.
Kia Motesharei, Ph.D., President and Chief Operating Officer of ReAlta, also emphasized the strategic importance of the financing. She noted that the additional capital will enable the company to execute on key value inflection points with a disciplined and focused approach. These inflection points include not only clinical milestones such as trial completion and data readouts, but also regulatory engagements that will define the future development pathway for pegtarazimod.
Motesharei underscored the company’s commitment to deploying capital efficiently while maintaining a strong focus on generating meaningful outcomes for patients and stakeholders. She described ReAlta’s efforts as the creation of an entirely new category of medicine for HIE, where currently no pharmacological treatment exists. The goal, she explained, is not simply to achieve incremental improvements over existing supportive care measures, but to introduce a transformative therapy that can significantly alter disease progression and improve long-term outcomes for affected infants.
The broader scientific foundation of ReAlta’s approach is rooted in the role of the complement system and neutrophils in inflammatory diseases. The complement system is a critical component of the innate immune response, involved in pathogen defense and inflammation. However, dysregulated complement activation can contribute to tissue damage in a variety of conditions, including ischemic injuries. Similarly, neutrophils, which are among the first immune cells to respond to injury, can exacerbate inflammation and contribute to secondary damage if not properly regulated.
By developing therapies that simultaneously target these interconnected pathways, ReAlta aims to create a more comprehensive and effective approach to managing inflammatory diseases. While the current focus is on HIE, the company’s platform may have broader applications across other conditions characterized by excessive or dysregulated inflammation.
The successful completion of this financing round reflects growing investor interest in innovative approaches to treating complex and underserved conditions. It also highlights the increasing recognition of the importance of addressing neonatal diseases, which have historically received less attention in drug development compared to adult conditions. As advancements in neonatal care continue to improve survival rates, there is a corresponding need for therapies that can improve long-term outcomes and quality of life for survivors.
Looking ahead, ReAlta is positioned to enter a critical phase in its development journey. The results of the Phase 2 STAR trial will be closely watched by the medical and scientific community, as they will provide important insights into the potential efficacy of pegtarazimod in a patient population with significant unmet need. Positive outcomes could pave the way for larger, pivotal studies and eventual regulatory submissions.
In summary, ReAlta Life Sciences’ $40 million financing marks a significant step forward in the development of pegtarazimod and the company’s broader mission to transform the treatment of inflammatory diseases. By focusing on innovative mechanisms of action and addressing a critical gap in neonatal care, ReAlta is working to redefine therapeutic possibilities for Hypoxic Ischemic Encephalopathy and potentially improve outcomes for thousands of newborns and their families worldwide.
About ReAlta Life Sciences
ReAlta Life Sciences is a clinical-stage biopharmaceutical company redefining the treatment possibilities for patients with devastating and historically untreatable inflammation-driven diseases by developing first-in-class tailored peptides designed to achieve life-changing outcomes with unprecedented safety. The company’s lead candidate, pegtarazimod (RLS-0071), is a next-generation dual-targeting intervention that represents a solution that rebalances the body’s inflammatory response and prevents tissue damage by selectively blocking both complement- and neutrophil-mediated pathways at the outset, disrupting inflammation at the core. To learn more about ReAlta, visit https://realtalifesciences.com and follow us on LinkedIn.
About RLS-0071 (pegtarazimod)
Pegtarazimod is a 15-amino-acid peptide that uniquely targets both humoral and cellular inflammation and is the Company’s lead therapeutic candidate. The peptide works by inhibiting complement activation at C1, as well as myeloperoxidase activity and neutrophil extracellular trap (NET) formation—key mechanisms implicated in the inflammatory cascade underlying a broad range of diseases driven by dysregulated neutrophils and complement activity. Pegtarazimod was derived from a mechanistic discovery of the human astrovirus HAstV-1, a virus known to cause non-inflammatory gastroenteritis, which provided a novel scaffold for innate immune modulation.
Across multiple clinical studies in healthy volunteers and patients with life-threatening inflammatory conditions, pegtarazimod has demonstrated a favorable tolerability profile and encouraging clinical signals, supporting its development in acute inflammatory diseases with significant unmet medical need. Pegtarazimod has received FDA Orphan Drug and Fast Track Designations for Hypoxic Ischemic Encephalopathy (HIE) and EMA Orphan Drug Designation for HIE.
About Hypoxic Ischemic Encephalopathy (HIE)
Hypoxic Ischemic Encephalopathy (HIE) is a serious and often devastating form of neonatal brain injury caused by a lack of oxygen and blood flow to the brain during or around the time of birth. HIE affects thousands of newborns each year in the United States and globally and remains a leading cause of neonatal mortality and long-term neurological disability, including cerebral palsy, epilepsy, and cognitive impairment.
Therapeutic hypothermia is currently the standard of care and has been shown to provide modest benefit in some infants; however, there are currently no approved drug therapies that directly target the underlying inflammatory injury that contributes to brain damage following hypoxic ischemic events. As a result, there remains a significant unmet medical need and a potentially multi-billion-dollar global market opportunity for therapies that can meaningfully improve neurological outcomes in affected infants.
About the STAR Trial
The STAR trial (NCT05778188) is a two-stage, randomized, double-blind, placebo-controlled study currently enrolling patients across 13 NICUs in the United States, evaluating RLS-0071 (pegtarazimod) in newborns with moderate or severe HIE undergoing therapeutic hypothermia.
Source Link:https://www.businesswire.com/
